Comparison · NCT06680206-e60d62c2
Rimegepant (Users With <12 Days of Use) vs Triptans: Number of Participants With Family Practitioner Visits in Past 6 Months- Sensitivity Analysis
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Rimegepant (Users With <12 Days of Use) vs Triptans: Number of Participants With Family Practitioner Visits in Past 6 Months- Sensitivity Analysis. Trial comparisons, record NCT06680206-e60d62c2. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT06680206-e60d62c2
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.738 | 0.645 | 0.813 | wilson | |
| Risk in group 2 | 0.776 | 0.753 | 0.799 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0386 | -0.134 | 0.0404 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.95 | 0.844 | 1.07 | log | |
| Odds ratio, group 1 over group 2 | 0.81 | 0.512 | 1.28 | log | |
| Number needed to treat, for one fewer participant with the outcome on Rimegepant (Users With <12 Days of Use) than on Triptans | 25.9 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Rimegepant (Users With <12 Days of Use) | Participants who were acute rimegepant users with days of use \< 12 days per month for migraine at the time of survey (NHWS in Year 2023) were included. No intervention was administered as a part of this study. | 76 | 103 | OG000 |
| Group 2 | Triptans | Participants who responded to use triptans orally for migraine at the time of survey (NHWS in Year 2023) were included. No intervention was administered as a part of this study. | 976 | 1,257 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With Family Practitioner Visits in Past 6 Months- Sensitivity Analysis
- Description
- Analysis was performed using IPTW method to adjust for confounding by the covariates.
- Time frame
- 6 months before the survey was taken, during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.
- Population
Analysis population included all eligible participants whose data were retrieved and observed in the study. For sensitivity analysis a subset of rimegepant users with less than 12 days of rimegepant use per month were included and the numbers were adjusted using IPTW method, which created pseudo population, leading to difference from the sample sizes before IPTW.
Source ClinicalTrials.gov
Trial
- Title
- Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey
- NCT number
- NCT06680206
- Phases
- Conditions
- Migraine
- Interventions
- Rimegepant, Triptans
- Lead sponsor
- Pfizer
- Results first posted
- 2026-01-22
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT06680206?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT06680206-e60d62c2